|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 2.210 USD | +0.45% |
|
+13.33% | -8.30% |
| Market Cap | 94.71M 81.13M 75.91M 69.48M 130M 9.06B 132M 897M 350M 4.55B 356M 348M 15.06B | P/E 2026 * |
-1.16x | P/E 2027 * | -1.36x |
|---|---|---|---|---|---|
| Enterprise Value | 94.71M 81.13M 75.91M 69.48M 130M 9.06B 132M 897M 350M 4.55B 356M 348M 15.06B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
84.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Acrivon Therapeutics, Inc.
| 1 day | +0.45% | ||
| 1 week | +13.33% | ||
| Current month | +47.33% | ||
| 1 month | +32.34% | ||
| 3 months | +26.29% | ||
| 6 months | +47.33% | ||
| Current year | -8.30% |
| 1 week | 1.97 |  | 2.39 |
| 1 month | 1.41 | | 2.39 |
| Current year | 1.27 | | 3.56 |
| 1 year | 1.27 | | 3.56 |
| 3 years | 1.05 | | 12.52 |
| 5 years | 1.05 | | 25.47 |
| 10 years | 1.05 | | 25.47 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kristina Masson
COO | Chief Operating Officer | 46 | 2018-02-28 |
| Chief Executive Officer | 64 | 2018-03-31 | |
Adam Levy
DFI | Director of Finance/CFO | 60 | 2025-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 64 | 2018-03-31 | |
Kristina Masson
BRD | Director/Board Member | 46 | 2018-02-28 |
Sharon Shacham
BRD | Director/Board Member | 55 | 2020-09-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/18/26 | Sell | General Counsel | -185 | 0.0004% | ||
| 8/18/26 | Sell | Chief Executive Officer | -1,713 | 0.0040% | ||
| 8/18/26 | Sell | Executive/Senior Manager | -400 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.45% | +13.33% | +62.50% | -80.78% | 94.71M | |
| -0.62% | +3.71% | +2.55% | +23.02% | 51.61B | |
| -1.07% | +2.82% | +465.96% | +570.70% | 44.89B | |
| +1.47% | +9.79% | +35.92% | +20.21% | 42.77B | |
| +1.44% | +7.77% | +19.38% | +84.65% | 42.58B | |
| -0.93% | -4.33% | +16.18% | +55.82% | 31.82B | |
| +1.32% | +7.30% | +33.89% | +148.53% | 17.33B | |
| -0.60% | +1.93% | - | - | 16.63B | |
| +0.19% | +4.29% | +9.38% | +30.40% | 14.76B | |
| +1.28% | +5.41% | +82.40% | +46.13% | 14.09B | |
| Average | +0.29% | +5.32% | +80.91% | +99.85% | 27.66B | |
| Weighted average by Cap. | +0.17% | +4.72% | +99.33% | +141.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -76.59M -65.6M -61.38M -56.19M -105M -7.33B -107M -725M -283M -3.68B -288M -281M -12.18B | -90.84M -77.82M -72.81M -66.65M -125M -8.69B -127M -860M -335M -4.37B -341M -334M -14.44B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-21 | US$2.210 | +0.45% | 361,333 |
| 26-08-20 | US$2.200 | -7.95% | 499,427 |
| 26-08-19 | US$2.390 | +16.59% | 731,493 |
| 26-08-18 | US$2.050 | 0.00% | 336,372 |
| 26-08-17 | US$2.050 | +5.13% | 1,501,261 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACRV Stock
Select your edition
All financial news and data tailored to specific country editions
